Curbing the influence of the drug industry: a British view
Smith explores the implications of a recent report from Britain's House of Commons Health Committee that examined the pharmaceutical industry's influence upon medicine. A recent report from politicians in Britain recommends a fundamental review of drug development, marketing, and prescribi...
Gespeichert in:
| Veröffentlicht in: | PLoS medicine 2005-09, Vol.2 (9), p.e241-e241 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e241 |
|---|---|
| container_issue | 9 |
| container_start_page | e241 |
| container_title | PLoS medicine |
| container_volume | 2 |
| creator | Smith, Richard |
| description | Smith explores the implications of a recent report from Britain's House of Commons Health Committee that examined the pharmaceutical industry's influence upon medicine.
A recent report from politicians in Britain recommends a fundamental review of drug development, marketing, and prescribing practices |
| doi_str_mv | 10.1371/journal.pmed.0020241 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_plos_</sourceid><recordid>TN_cdi_plos_journals_1288069918</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_9b79edb3d45c4bc699ae12257a5c42bc</doaj_id><sourcerecordid>2893114721</sourcerecordid><originalsourceid>FETCH-LOGICAL-c524t-65b26cb4d5bc17e19888ce70b72b83f90844ae7303a11eea27484059c13483673</originalsourceid><addsrcrecordid>eNptUk1vEzEUXCEQLYV_gGAlpN4S_PztHirRiI9KlbjA2bK9bxNHm3Wwd4v679k0C7SIk-3xzLw39quq10CWwBS836Yx965b7nfYLAmhhHJ4Up2C4GYBUsmnD_Yn1YtSthPJEEOeVycgiZKU09PqYjVmH_t1PWywjn3bjdgHrFN7DzR5XE9oM5Yh313Urr7KcYhlU99G_Pmyeta6ruCreT2rvn_6-G31ZXHz9fP16sPNIgjKh4UUnsrgeSN8AIVgtNYBFfGKes1aQzTnDhUjzAEgOqq45kSYAIxrJhU7q94effddKnaOXSxQrYk0BvTEuD4ymuS2dp_jzuU7m1y090DKa-vyEEOH1nhlsPGs4SJwHya9Q6BUKDedqQ-T1-VcbfTTywbsh-y6R6aPb_q4set0awE0CHZo93w2yOnHiGWwu1gCdp3rMY3FSi2JACIm4rt_iP_Pxo-skFMpGds_rQCxh0H4rbKHQbDzIEyyNw9j_BXNP89-ATx5r5w</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1288069918</pqid></control><display><type>article</type><title>Curbing the influence of the drug industry: a British view</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Smith, Richard</creator><creatorcontrib>Smith, Richard</creatorcontrib><description>Smith explores the implications of a recent report from Britain's House of Commons Health Committee that examined the pharmaceutical industry's influence upon medicine.
A recent report from politicians in Britain recommends a fundamental review of drug development, marketing, and prescribing practices</description><identifier>ISSN: 1549-1676</identifier><identifier>ISSN: 1549-1277</identifier><identifier>EISSN: 1549-1676</identifier><identifier>DOI: 10.1371/journal.pmed.0020241</identifier><identifier>PMID: 16076242</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Advisory Committees ; Attitude of Health Personnel ; Clinical Pharmacology ; Clinical trials ; Committees ; Conflict of Interest ; Drug Industry - ethics ; Drugs ; Drugs and adverse drug reactions ; Epidemiology/Public Health ; Evidence Based Practice ; General Medicine ; General Practice/Family Practice/Primary Care ; Gift Giving - ethics ; Guidelines as Topic ; Health Policy ; Humans ; Marketing - ethics ; Other ; Patients ; Persuasive Communication ; Pharmaceutical industry ; Pharmacology/Drug Discovery ; Physicians ; Primary Care ; Public Policy ; Publishing industry ; Regulation ; Scholarly publishing ; United Kingdom</subject><ispartof>PLoS medicine, 2005-09, Vol.2 (9), p.e241-e241</ispartof><rights>2005 Richard Smith. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Citation: Smith R (2005) Curbing the Influence of the Drug Industry: A British View. PLoS Med 2(9): e241. doi:10.1371/journal.pmed.0020241</rights><rights>Copyright: © 2005 Richard Smith. 2005</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c524t-65b26cb4d5bc17e19888ce70b72b83f90844ae7303a11eea27484059c13483673</citedby><cites>FETCH-LOGICAL-c524t-65b26cb4d5bc17e19888ce70b72b83f90844ae7303a11eea27484059c13483673</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1181537/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1181537/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2100,2926,23864,27922,27923,53789,53791,79370,79371</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16076242$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Smith, Richard</creatorcontrib><title>Curbing the influence of the drug industry: a British view</title><title>PLoS medicine</title><addtitle>PLoS Med</addtitle><description>Smith explores the implications of a recent report from Britain's House of Commons Health Committee that examined the pharmaceutical industry's influence upon medicine.
A recent report from politicians in Britain recommends a fundamental review of drug development, marketing, and prescribing practices</description><subject>Advisory Committees</subject><subject>Attitude of Health Personnel</subject><subject>Clinical Pharmacology</subject><subject>Clinical trials</subject><subject>Committees</subject><subject>Conflict of Interest</subject><subject>Drug Industry - ethics</subject><subject>Drugs</subject><subject>Drugs and adverse drug reactions</subject><subject>Epidemiology/Public Health</subject><subject>Evidence Based Practice</subject><subject>General Medicine</subject><subject>General Practice/Family Practice/Primary Care</subject><subject>Gift Giving - ethics</subject><subject>Guidelines as Topic</subject><subject>Health Policy</subject><subject>Humans</subject><subject>Marketing - ethics</subject><subject>Other</subject><subject>Patients</subject><subject>Persuasive Communication</subject><subject>Pharmaceutical industry</subject><subject>Pharmacology/Drug Discovery</subject><subject>Physicians</subject><subject>Primary Care</subject><subject>Public Policy</subject><subject>Publishing industry</subject><subject>Regulation</subject><subject>Scholarly publishing</subject><subject>United Kingdom</subject><issn>1549-1676</issn><issn>1549-1277</issn><issn>1549-1676</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>DOA</sourceid><recordid>eNptUk1vEzEUXCEQLYV_gGAlpN4S_PztHirRiI9KlbjA2bK9bxNHm3Wwd4v679k0C7SIk-3xzLw39quq10CWwBS836Yx965b7nfYLAmhhHJ4Up2C4GYBUsmnD_Yn1YtSthPJEEOeVycgiZKU09PqYjVmH_t1PWywjn3bjdgHrFN7DzR5XE9oM5Yh313Urr7KcYhlU99G_Pmyeta6ruCreT2rvn_6-G31ZXHz9fP16sPNIgjKh4UUnsrgeSN8AIVgtNYBFfGKes1aQzTnDhUjzAEgOqq45kSYAIxrJhU7q94effddKnaOXSxQrYk0BvTEuD4ymuS2dp_jzuU7m1y090DKa-vyEEOH1nhlsPGs4SJwHya9Q6BUKDedqQ-T1-VcbfTTywbsh-y6R6aPb_q4set0awE0CHZo93w2yOnHiGWwu1gCdp3rMY3FSi2JACIm4rt_iP_Pxo-skFMpGds_rQCxh0H4rbKHQbDzIEyyNw9j_BXNP89-ATx5r5w</recordid><startdate>20050901</startdate><enddate>20050901</enddate><creator>Smith, Richard</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><scope>CZK</scope></search><sort><creationdate>20050901</creationdate><title>Curbing the influence of the drug industry: a British view</title><author>Smith, Richard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c524t-65b26cb4d5bc17e19888ce70b72b83f90844ae7303a11eea27484059c13483673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Advisory Committees</topic><topic>Attitude of Health Personnel</topic><topic>Clinical Pharmacology</topic><topic>Clinical trials</topic><topic>Committees</topic><topic>Conflict of Interest</topic><topic>Drug Industry - ethics</topic><topic>Drugs</topic><topic>Drugs and adverse drug reactions</topic><topic>Epidemiology/Public Health</topic><topic>Evidence Based Practice</topic><topic>General Medicine</topic><topic>General Practice/Family Practice/Primary Care</topic><topic>Gift Giving - ethics</topic><topic>Guidelines as Topic</topic><topic>Health Policy</topic><topic>Humans</topic><topic>Marketing - ethics</topic><topic>Other</topic><topic>Patients</topic><topic>Persuasive Communication</topic><topic>Pharmaceutical industry</topic><topic>Pharmacology/Drug Discovery</topic><topic>Physicians</topic><topic>Primary Care</topic><topic>Public Policy</topic><topic>Publishing industry</topic><topic>Regulation</topic><topic>Scholarly publishing</topic><topic>United Kingdom</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Smith, Richard</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><collection>PLoS Medicine</collection><jtitle>PLoS medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Smith, Richard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Curbing the influence of the drug industry: a British view</atitle><jtitle>PLoS medicine</jtitle><addtitle>PLoS Med</addtitle><date>2005-09-01</date><risdate>2005</risdate><volume>2</volume><issue>9</issue><spage>e241</spage><epage>e241</epage><pages>e241-e241</pages><issn>1549-1676</issn><issn>1549-1277</issn><eissn>1549-1676</eissn><abstract>Smith explores the implications of a recent report from Britain's House of Commons Health Committee that examined the pharmaceutical industry's influence upon medicine.
A recent report from politicians in Britain recommends a fundamental review of drug development, marketing, and prescribing practices</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>16076242</pmid><doi>10.1371/journal.pmed.0020241</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1549-1676 |
| ispartof | PLoS medicine, 2005-09, Vol.2 (9), p.e241-e241 |
| issn | 1549-1676 1549-1277 1549-1676 |
| language | eng |
| recordid | cdi_plos_journals_1288069918 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Public Library of Science (PLoS); EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Advisory Committees Attitude of Health Personnel Clinical Pharmacology Clinical trials Committees Conflict of Interest Drug Industry - ethics Drugs Drugs and adverse drug reactions Epidemiology/Public Health Evidence Based Practice General Medicine General Practice/Family Practice/Primary Care Gift Giving - ethics Guidelines as Topic Health Policy Humans Marketing - ethics Other Patients Persuasive Communication Pharmaceutical industry Pharmacology/Drug Discovery Physicians Primary Care Public Policy Publishing industry Regulation Scholarly publishing United Kingdom |
| title | Curbing the influence of the drug industry: a British view |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T20%3A34%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Curbing%20the%20influence%20of%20the%20drug%20industry:%20a%20British%20view&rft.jtitle=PLoS%20medicine&rft.au=Smith,%20Richard&rft.date=2005-09-01&rft.volume=2&rft.issue=9&rft.spage=e241&rft.epage=e241&rft.pages=e241-e241&rft.issn=1549-1676&rft.eissn=1549-1676&rft_id=info:doi/10.1371/journal.pmed.0020241&rft_dat=%3Cproquest_plos_%3E2893114721%3C/proquest_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1288069918&rft_id=info:pmid/16076242&rft_doaj_id=oai_doaj_org_article_9b79edb3d45c4bc699ae12257a5c42bc&rfr_iscdi=true |